Author

E. Tsonou

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. D. Campbell· 1 shared A. F. Munro· 1 shared B. Serrels· 1 shared C. A. Ford· 1 shared C. Bull· 1 shared C. Nixon· 1 shared D. C. Hornigold· 1 shared D. Koludrovic· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. Campbell

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

C. A. Ford, D. Koludrovic, P. P. Centeno, M. Foth, E. Tsonou, N. Vlahov, N. Sphyris, K. Gilroy, C. Bull, C. Nixon, B. Serrels, A. F. Munro, J. C. Dawson, N. O. Carragher, V. Pavet, , A. D. Campbell

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

bioRxiv · Feb 26, 2024Cancer Biology